ArticleFrontiers in oncology2023

Preclinical characterization of CPL304110 as a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3 for gastric, bladder, and squamous cell lung cancer.

Delfina Popiel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.